Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHITECT study of alirocumab in familial hypercholesterolemia
2017-004299-69Phase 4Active
- Sponsor
- Fundación Hipercolesterolemia Familiar
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Fundación Hipercolesterolemia Familiar. Primary endpoint: Change in percent atheroma volume. Started Mar 2018; status: active.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2017-004299-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004299-69.